Si deseas distinguir tus productos, servicios o ambos de los de otra empresa, es posible que necesites una marca o nombre comercial. Descubre qué son, en qué consiste su procedimiento de registro y qué implica.
Información sobre los plazos de presentación de solicitudes de transformación de marcas de la Unión Europea en marca nacional española. Más información
Si tienes un nuevo dispositivo, producto o procedimiento que resuelva un problema técnico o tenga una ventaja práctica, existen distintas formas de protegerlo en España y en otros países. Descubre cómo hacerlo.
¿Tu innovación reside en la estética, la ornamentación o la apariencia de tu producto? Protégela mediante un diseño industrial. Descubre qué derechos confiere el registro y cómo realizar la tramitación.
Las indicaciones geográficas protegen el nombre de un producto originario de una zona geográfica, a la cual le debe una determinada calidad, reputación u otra característica. Descubre qué son, en qué consiste su procedimiento de registro y qué beneficios conceden.
Las patentes publicadas en todo el mundo son una valiosa fuente de información científica, técnica y comercial.
Si eres emprendedor/a o una empresa y quieres potenciar y mejorar la rentabilidad de tu negocio protegiendo de forma adecuada los activos intangibles de tu organización, en este espacio encontrarás lo necesario.
369
resultados
Última actualización
17/10/2026 [08:09:00]
Resultados 300 a 325 de 369
Resumen de: US20260251634A1
A method of analyzing neurons includes: identifying a cell region by identifying a region of a neurite or a region of a cell body of a neuron on the basis of time-series images obtained by imaging the neuron in time series; detecting aggregates by imaging, in time series, first fluorescent protein tagged to specific protein expressed in the neuron and detecting presence or absence of aggregates of the specific protein aggregated in the region of the neurite or the region of the cell body identified in the identifying the cell region on the basis of luminance of the first fluorescent protein included in the time-series images; and performing an analysis by classifying the neuron into a plurality of groups on the basis of a detection result of the detecting the aggregates and analyzing a survival state of the neuron for each of the groups.
Resumen de: AU2025374616A1
Methods of detecting analytes in a sample are described herein using chemiluminescent labels and branched DNA. Solid supports, reagents, and compounds for use in these methods are also described. Typically, the methods involve specific assay formats which provide the requisite high resolution for detecting low concentrations of analytes such as exosome protein biomarkers in samples.
Resumen de: US20260251655A1
0000 The present invention is directed to methods for determining the level of PAM and/or its isoforms and/or fragments thereof in a bodily fluid or a tissue sample using an assay, wherein said assay is comprising at least one binder that is directed to a conformational epitope of PAM, and its use for diagnostic purpose.
Resumen de: WO2026176371A1
The present disclosure is related to drug delivery compositions containing extracellular vesicles having a therapeutic by utilizing visceral sensory neurons, a method using thereof for delivering the drugs to central nervous system and an organoid on chip model comprising a three-compartment axis-on-a chip for testing delivery of the drug containing EV over BBB, wherein the compositions comprising bacterial extracellular vesicles (EV) and therapeutics, wherein the drug or the therapeutic is encapsulated within the EV or attached or conjugated to EV.
Resumen de: WO2026178362A1
Described herein are polypeptide useful for identifying compound for modulating aberrant protein condensates. The polypeptide comprise a condensate-modulating protein, a first biomarker polypeptide, a barcoding biomarker polypeptide. When inside a cell, the non-natural polypeptide exist as multiple fragments, including a first fragment comprising the condensate-modulating protein and the first biomarker polypeptide, and a second fragment comprising the barcoding biomarker polypeptide. The barcoding biomarker polypeptide is uniquely associated with and identifies the cell expressing associated condensate-modulating protein. Also described is a polynucleotide encoding the non-natural polypeptide, a library of the polynucleotide, and a method of identifying compound for modulating aberrant protein condensates using the non-natural polypeptide, the construct, and/or the library.
Resumen de: WO2026178077A1
The present disclosure relates to methods and compositions for editing an AMPK polynucleotide encoding an AMPK protein. The disclosure also relates to methods and compositions for modulating activity of an AMPK protein, for promoting activation of an AMPK protein, for repairing function of a pathogenic AMPK protein, and methods for regulating energy homeostasis and/or for treating or preventing an AMPK-associated disease or condition in a subject.
Resumen de: WO2026176083A1
The present invention relates to a method for diagnosing a patient having a neurological (including neuromuscular) disorder, such as ALS. The invention further relates to a method for distinguishing between neurological disorders, said method extending to include the ability to discriminate one subtype from other subtypes of the same disorder.
Resumen de: WO2026175415A1
Disclosed is a preparation technical method capable of preparing a large number of pathogenic tau proteins having a pathological conformation similar to that in the brain of a patient with neurodegenerative diseases by means of in vitro preparation and continuous multi-round amplification. The method can achieve continuous multi-round amplification of a patient brain-derived pathological tau protein by using only a small amount of the patient brain-derived pathological protein as a template, a recombinant human-derived tau protein monomer, and a negatively charged polyanion compound as an inducing cofactor, thereby achieving the in vitro preparation of a large amount of the pathological tau protein. In addition, the pathological tau protein prepared by the method can maintain the special pathological conformation of the original tau protein of the disease, has the same pathological activity as the original tau protein, and can be used for probe screening, antibody preparation, and verification model development.
Resumen de: WO2026177204A1
The purpose of the present invention is to provide a novel naturally derived cellular vesicle staining agent that can easily fluorescently stain cellular vesicles and that is safe even when introduced into the body, and to provide a cellular vesicle staining agent having anti-inflammatory activity. The purpose of the present invention is also to provide a method for producing a cellular vesicle staining agent, whereby the cellular vesicle staining agent can be easily produced. Another purpose of the present invention is to provide a method for detecting cellular vesicles using the cellular vesicle staining agent. The present invention provides: a cellular vesicle staining agent comprising chlorophyll or a chlorophyll derivative; an anti-inflammatory agent comprising chlorophyll or a chlorophyll derivative as an active ingredient; a method for producing a cellular vesicle staining agent, the method comprising a step for extracting a cellular vesicle staining agent from a photosynthetic organism; and a method for detecting a cellular vesicle in a sample or in a body using the cellular vesicle staining agent.
Resumen de: WO2026178110A1
Disclosed is a method for the treatment of major depressive disorder (MDD), which includes administering to a human subject suffering from MDD, a therapeutically effective amount of an antibody selected from fezakinumab, ustekinumab, gusacitinib and dupilumab, and combinations thereof.
Resumen de: US20260251541A1
0000 The present invention relates to a method of fixing extracellular vesicles. The method includes providing a sample containing extracellular vesicles and contacting the sample with a non-reversible cross-linking agent and, optionally, an aldehyde-containing fixative. Preferably the non-reversible cross-linking agent is 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide. The method also includes imaging the fixed extracellular vesicles for the determination or exclusion of disease or disorder in a clinical sample. The present invention also relates to a kit for fixing extracellular vesicles in a biological sample.
Resumen de: US20260251664A1
0000 The present disclosure includes biomarkers, methods, devices, reagents, systems, and kits for the evaluation of risk of dementia in a middle-aged individual within a specified timeframe, for example 5, 10, 15 and/or 20 years. In one aspect, the disclosure provides biomarkers that can be used alone or in various combinations to evaluate risk of dementia within 5, 10, 15 and/or 20 years. In another aspect, methods are provided for evaluating risk of dementia within 5, 10, 15 and/or 20 years in a middle-aged individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 6.
Resumen de: US20260251557A1
0000 A method includes contacting one or more volatile organic compounds (“VOCs”) evolved from a sample to one or more detection regions configured for sensitivity against one or more VOCs. The contacting causes a change to the detection regions that is visible to the human eye. The method also includes determining the presence or absence of a VOC by comparing the change to the detection regions to a key, with the key being a visible change. A system utilizing the method is also described.
Resumen de: US20260251650A1
0000 The invention relates to neurodegenerative disorders, and the diagnosis and/or prognosis of neurodegenerative disorders in a test subject using a lateral flow test, or the like. The invention also relates to detecting diagnostic and prognostic biomarkers in a range of various patient sample types for diagnosing and/or prognosing neurodegenerative disorders, such as Alzheimer's disease. The invention further provides biomarker detection methods, and apparatus and apparatuses for diagnosing and prognosing neurodegenerative disorders, and methods of treating patients diagnosed or prognosed with a neurodegenerative disorder. The invention also extends to detection of biomarkers and/or screening in pre-symptomatic subjects, for early diagnosis, to enable disease prevention or intervention.
Resumen de: US20260251665A1
0000 A method of aiding diagnosis of a disease or condition in a subject, wherein the method comprises comparing a level of at least one natriuretic peptide detected in a biological sample obtained from the subject with a reference level of the at least one natriuretic peptide, wherein the biological sample is an oral mucosal transudate (OMT) sample obtained from one or more mucous membranes inside the mouth of the subject.
Resumen de: US20260251568A1
Disclosed herein is a device for chiral sensing comprising a chiral plasmonic substrate, wherein when the device is assembled together with a first light source, a liquid sample comprising a plurality of chiral analytes, a second light source, and an instrument, the first light source is configured to illuminate the chiral plasmonic substrate with electromagnetic radiation; and the second light source is configured to illuminate the chiral plasmonic substrate with circularly polarized electromagnetic radiation. The instrument is configured to process electromagnetic signal from the first light source and the second light source to determine a property of the liquid sample.
Resumen de: WO2025081242A1
The present disclosure relates to compositions comprising a solid surface and two or more capture agents that bind to extracellular vesicles (EVs) for capturing EVs derived from cells of the nervous system. The present disclosure further relates to methods or uses of such compositions for treating, diagnosing and/or assessing the likelihood of a subject suffering from a neurodegenerative disease.
Resumen de: WO2025085755A1
Disclosed are methods of detecting or quantifying a pathology -related or pathology-protective-pathway in a subject comprising combining a first ligand with a sample obtained from the subject comprising an extracellular particle, wherein the first ligand binds to a cell-type specific marker on the extracellular particle; combining a second ligand with the sample, wherein the second ligand binds to a pathology-related or pathology-protective pathway molecule on the extracellular particle; combining a donor bead to the sample, wherein the donor bead binds to the first ligand or second ligand; combining an acceptor bead to the sample, wherein the acceptor bead binds to the first ligand or second ligand, wherein the donor bead and acceptor bead do not bind to the same ligand; triggering the donor bead to activate the acceptor bead to produce a signal; wherein the amount, presence, or absence of a signal indicates the amount, presence, or absence of a pathological condition in the subject.
Resumen de: EP4796928A1
The present disclosure relates to an in vitro method for diagnosing Alzheimer's disease (AD) in a subject, the method comprising a step of determining the level of β-secretase 1 protein (BACE-1) comprised in a population of brain-derived extracellular vesicles (BDEVs) in an isolated sample obtained from the subject, particularly wherein the population of BDEVs carry neuroligin-3 (NLGN3), wherein when the level of BACE-1 is equal to or higher than a reference this is indicative of a positive diagnosis of Alzheimer's disease. Also provided herein are methods of determining the classification of a subject according to the A/T/N system, methods for recommending a medical regimen, methods for determining therapeutic efficacy of a medical regiment, as well as methods of treatment for AD and AD-associated pathologies in a subject. Finally, the present disclosure provides kits and devices comprising: a) means for capturing a population of brain-derived extracellular vesicles; b) means for detecting the presence and/or for determining the level of BACE-1 protein; and optionally, c) a solid support.
Resumen de: EP4796929A2
0001 A method is provided for determining the presence of soluble, misfolded α-synuclein protein in a biological sample. The method comprises contacting the biological sample with a pre-incubation mixture, the pre-incubation mixture comprising: a monomeric α-synuclein protein; a buffer composition; a salt; and an indicator, to form an incubation mixture. An incubation cycle is conducted on the incubation mixture in the presence of either a silicon nitride bead or a borosilicate glass bead having a diameter of from about 1 mm to about 5 mm. The method further comprises determining if a detectable amount of misfolded α-synuclein aggregate is present in the biological sample.
Resumen de: EP4796930A2
Disclosed herein are methods of detecting a plurality of targets comprising different nucleic acid sequences or different proteins within an optically resolved volume of a cell in situ.
Resumen de: CN122628189A
0001 本申请公开了一种用于磷酸化Tau蛋白pTau217检测的抗体、免疫检测方法及应用。本申请抗体包括T217‑3D6抗体；T217‑3D6的轻链CDR1、CDR2和CDR3依序为SEQ ID NO.1至3所示序列，重链CDR1、CDR2和CDR3依序为SEQ ID NO.4至6所示序列。基于本申请抗体对磷酸化Tau蛋白pTau217进行免疫检测，操作简单、灵敏度高、特异性强，可实现磷酸化Tau蛋白pTau217快速检测，对评估Tau蛋白磷酸化水平和Tau蛋白pTau217磷酸化相关检测具有重要意义。
Resumen de: CN122631899A
0001 本发明公开了一种用于诊断HIV相关无症状神经认知障碍（ANI）的外泌体特征蛋白组合物，包括以下特征蛋白：DSCAM、IGF1、CAMK2D、UPF1、ALDH2、EIF5A；与非ANI人群相比，ANI人群中DSCAM和IGF1的相对丰度升高，CAMK2D、UPF1、ALDH2和EIF5A的相对丰度降低。该外泌体特征蛋白组合物具有以下优势：（1）诊断精准度高，能够全面覆盖ANI病理机制核心通路，可精准识别ANI患者；（2）特异性强，可清晰反映ANI患者外泌体蛋白的特异性表达模式，从而有效区分ANI与NCI及健康人群；（3）无创便捷，可基于外周血浆进行检测，提高受试者依从性，适合大规模筛查和长期随访；（4）易临床转化：针对上述外泌体特征蛋白制备的试剂盒操作简便，可规模化生产和使用，在各级医院、疾控中心均可落地，适宜推广应用。
Resumen de: CN122631732A
本发明公开了一种通用表位分子印迹膜转移到二维表面构建场效应晶体管用于检测生物标志物的方法，基于在铜箔表面制备表位印迹膜，刻蚀去除铜箔后将其转移到二维材料表面制备成场效应晶体管的生物检测方法，属于生物传感器技术领域；首先将糖化氨基酸序列作为表位分子，并通过硼酸亲和力固定到铜箔表面；通过能够与模板相互作用的多种功能单体印迹形成膜；刻蚀去除铜箔基底，即得到独立的表位分子印迹膜，该膜可以转移到任何二维材料表面；该发明首次实现表位分子印迹膜的转移，并充分利用了分子印迹的高选择性，以及二维材料的超灵敏特点，可实现生物样品的高特异性，快速、超敏的检测。
Nº publicación: CN122629217A 25/08/2026
Solicitante:
首都医科大学附属北京佑安医院
Resumen de: CN122629217A
0001 本发明公开了一种用于HIV相关无症状神经认知障碍（ANI）诊断的代谢组学‑肠道微生物标志物组合，包括代谢组学标志物和肠道微生物标志物，其中代谢组学标志物包括血浆标志物和粪便标志物，血浆标志物包括Asp‑Asn和花生四烯酸，粪便标志物包括组氨酸、赖氨酸、鸟氨酸以及吲哚乳酸；肠道微生物标志物包括门水平标志物和属水平标志物，门水平标志物包括厚壁菌门、放线菌门以及变形菌门微生物，属水平标志物包括普拉梭菌属、小杆菌属、克雷伯氏菌属以及普雷沃氏菌属。该标志物组合整合了代谢组学与肠道微生物的核心差异特征，诊断特异性和敏感性高，能够有效区分ANI患者与CI患者及健康人群，为HAND靶向干预提供了明确靶点，具有重要的临床应用价值。
BOPI
Sede Electrónica
